Buy 2-FMA Capsules 50mg

Product Overview

2-FMA Capsules 50mg, registered under CAS 1780004-19-4, provide a high-purity (≥98%) research chemical in pre-filled gelatin capsule format exclusively for laboratory and analytical investigations. As a brandless substituted amphetamine analog, this compound equips researchers with a standardized tool for examining fluorinated phenethylamine derivatives in synthetic pathways, neurotransmitter analog profiling, and forensic reference development. Professional laboratories favor the capsule delivery for its metering precision, eliminating manual weighing errors during method optimization and quantitative assays. The 50mg fill weight ensures compatibility with microscale protocols across HPLC, GC-MS, and NMR workflows. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

This encapsulation technology aligns with contemporary high-throughput research demands, where reproducibility and contamination control drive experimental integrity. Investigators leverage such formats to streamline multi-analyte calibrations and stability studies without matrix interferences.

Chemical Identity & Classification

2-FMA corresponds to CAS 1780004-19-4 (hydrochloride salt), with molecular formula C10H14FN- HCl and molecular weight 203.68 g/mol. Primary synonyms include 2-Fluoromethamphetamine hydrochloride, o-Fluoromethamphetamine HCl, and N,α-dimethyl-2-fluoro-1-phenyl-ethanamine monohydrochloride. It classifies as a ortho-fluoro substituted methamphetamine analog within the amphetamine family, designated primarily as an analytical reference standard for chromatographic calibration, mass spectral library development, and synthetic organic chemistry research.

Universal acceptance of these identifiers across PubChem, Reaxys, and Cayman Chemical repositories facilitates seamless literature cross-referencing and regulatory documentation. The hydrochloride moiety imparts enhanced aqueous solubility critical for LC-MS electrospray ionization efficiency.

Chemical & Physical Characteristics

Each capsule contains uniform white to off-white powder, demonstrating solubility profiles of >25 mg/mL in DMSO, 20 mg/mL in methanol/acetonitrile (50:50), and 8-12 mg/mL in ammonium formate buffer (10 mM, pH 3.5). Thermal decomposition onset exceeds 210°C under nitrogen, with vapor pressure negligible at ambient conditions (<10^-5 mmHg). Capsule shells dissolve completely within 15 minutes in simulated gastric fluid (USP <711>), releasing actives proportionally for dissolution testing. Hygroscopicity remains low (<5% weight gain at 90% RH/25°C), supporting extended bench stability.

These parameters optimize integration into reverse-phase UHPLC gradients, headspace GC analyses, and polarimetry for chiral purity assessments. Physical uniformity exceeds Ph. Eur. 2.9.40 content uniformity specifications (CV <2.5%).

Purity & Analytical Verification

Batches consistently deliver ≥98% purity, quantified by area-normalized RP-HPLC (C18, 0.1% TFA/acetonitrile gradient, 254 nm), EI-GC-MS (m/z 58 base peak), quantitative 13C-NMR (CD3OD, 500 MHz), and QTOF-HRMS (exact mass 168.1039 [M+H]+). Total related substances cap at 1.0%, with specified fluoroanisole intermediates <0.3% and enantiomeric excess >98% (S-enantiomer predominant). Comprehensive COA encompasses system suitability chromatograms, UV-Vis spectra (λmax 252 nm), and accelerated stability data (40°C/75% RH, 6 months), digitally accessible via serialized QR codes.

Multi-orthogonal validation per USP <1225> ensures defensibility in peer-reviewed publications and accreditation audits. Impurity elution order facilitates co-elution risk assessment in complex mixtures.

Quality Control & Batch Integrity

Capsule filling employs automated encapsulation under laminar flow (ISO 5), with NIR-chemical imaging for 100% blend homogeneity verification (RSD <1.5%). Full traceability links incoming API CoA through HPLC raw data to final release, retaining 200% overage for OOS investigations. Manufacturing controls temperature (20-25°C), humidity (40-60% RH), and differential pressure (>15 Pa), complemented by real-time particle counting (≤10 particles ≥5 μm). Third-party DEA Schedule I proficiency testing confirms identity.

This cGMP-inspired framework (21 CFR 211.110) guarantees inter-batch equivalence for pharmacokinetic modeling and long-term fate studies.

Safety, Handling & Laboratory Precautions

Process under extracted airflow fume hoods (>100 fpm) with Category C PPE ensembles: 21 mil Viton®/neoprene gloves, chemical splash goggles (D3 seal), disposable coveralls (Tychem® 2000), and half-face APRs (cartridges 60921/60923). Deploy primary/secondary containment (500 mL Nalgene® bottles), with 10% Na2CO3 neutralization for spills >10 g. Restrict to certified fume hood users per ANSI Z9.14, integrating SDS into digital chemical hygiene plans. LD50 (composite matrix) guides GHS H300 classification.

Alignment with NFPA 45 fire codes and EU 1272/2008 CLP regulations prioritizes collective protection hierarchies.

Packaging, Labeling & Storage

Capsules array in desiccant-filled HDPE bottles (30-100 count) with induction-sealed child-resistant closures and tamper-evident rings, nested in UN-approved secondary packaging. Labels specify CAS, fill weight, HPLC purity, mfg/expiry (24 months), and RFID-tracked lot codes per 21 CFR 211.120. Store at 15-30°C (<60% RH), avoiding copper/alkali metals; validated excursions to 40°C/75% RH retain >97% assay. Capsule integrity testing (USP <701>) confirms <0.1% leakage.

Pharmacopeial-compliant configuration supports GLP chain-of-custody from synthesis to analysis.

Intended Research Use & Market Positioning

2-FMA Capsules 50mg excel in substituted cathinone/amphetamine differentiation via differential mobility spectrometry, serving forensic casework (NPS scheduling), transporter uptake inhibition assays (NET/DAT selectivity ratios), and QSAR scaffold expansions for TAAR1 ligands. Toxicology labs calibrate urine/blood screening immunoassays; pharma screens hERG liability in lead optimization. Graduate programs integrate into designer drug metabolism mapping via CYP450 microsome incubations.

Premium capsule positioning captures 25% analytical standards market share versus bulk powders, driven by workflow efficiency gains.

Ordering, Availability & Fulfillment

Rolling 4-week synthesis horizons sustain >98% service levels through WooCommerce v9.x PCI Level 1 compliance, processing Visa/MC/crypto with 3D Secure 2.0. Fulfillment tiers domestic Priority Overnight (24h SLA) and international EMS (5-10d) with End-User Declarations. Client portal enables real-time tracking, COA batch printing, and retest scheduling. Academic/government POs net 30 terms.​

Operational agility matches grant cycle cadences.

Legal & Regulatory Disclaimer

Distribution limited to bona fide laboratory research, prohibiting human/veterinary administration, diagnostic/therapeutic deployment, or consumptive applications. Recipients attest regulatory familiarity encompassing 21 USC 813 analogues, EU 2005/387/JHA NPS, and national implementations. No liability assumed for unauthorized diversions; jurisdictional pre-clearance mandatory. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.